Table 3.
Expression of Fas, FasL, Par‐4, PHLDA1, caspase‐3, Ki‐67, Bcl‐2, Survivin, MUC1, and SPARC proteins in different stages of human salivary gland morphogenesis
| Pro‐apoptotic | Anti‐apoptotic | Remodelling/maturation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fas | FasL | Par‐4 | PHLDA1 | Caspase‐3 | Ki‐67 | Bcl‐2 | Survivin | MUC1 | SPARC | |
| Initial bud | + | + | ++ | ++ | 0 | + | + | ++ | 0 | 0 |
| Pseudoglandular | 0 | 0 | + | + | 0 | ++ | + | ++ | ++ | 0 |
| Canalicular | 0 | 0 | + | + | 0 | + | 0 | + | ++ | 0 |
| Terminal bud | 0 | 0 | 0 | 0 | 0 | + | 0 | + | ++ | 0 |
(++) Strong expression; (+) weak expression; (0) no expression; Fas, Fas cell surface death receptor; FasL, Fas ligand; Par‐4, prostate apoptosis response‐4; PHLDA1, pleckstrin homology‐like domain family A member 1; Bcl‐2, B‐cell CLL/lymphoma 2; MUC1, mucin 1; SPARC, secreted protein acidic and cysteine‐rich.